HRAS-driven cancer cells are vulnerable to TRPML1 inhibition.
Jung J, Cho KJ, Naji AK, Clemons KN, Wong CO, Villanueva M, Gregory S, Karagas NE, Tan L, Liang H, Rousseau MA, Tomasevich KM, Sikora AG, Levental I, van der Hoeven D, Zhou Y, Hancock JF, Venkatachalam K.
Jung J, et al. Among authors: wong co.
EMBO Rep. 2019 Apr;20(4):e46685. doi: 10.15252/embr.201846685. Epub 2019 Feb 20.
EMBO Rep. 2019.
PMID: 30787043
Free PMC article.